Clarion call for trials assessing "cardiopulmonary" agents to reduce morbidity and mortality in inflammatory lung diseases

Chest. 2007 Apr;131(4):950-1. doi: 10.1378/chest.06-2838.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Animals
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Incidence
  • Pneumonia / drug therapy
  • Pneumonia / epidemiology*
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Pulmonary Disease, Chronic Obstructive / epidemiology*
  • Randomized Controlled Trials as Topic*
  • Survival Rate / trends
  • United States / epidemiology

Substances

  • Adrenergic beta-Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors